Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
1(9%)
Results Posted
22%(2 trials)

Phase Distribution

Ph phase_2
3
27%
Ph phase_3
1
9%
Ph phase_1
6
55%

Phase Distribution

6

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
6(60.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(1)
Completed(9)
Other(1)

Detailed Status

Completed9
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (60.0%)
Phase 23 (30.0%)
Phase 31 (10.0%)

Trials by Status

active_not_recruiting19%
unknown19%
completed982%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT05090904Phase 2

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Completed
NCT06685835Phase 2

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

Active Not Recruiting
NCT06013241Phase 2

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Completed
NCT05344508

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Unknown
NCT06178783Phase 1

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Completed
NCT05965570Phase 1

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Completed
NCT04817332Phase 3

STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19

Completed
NCT05826574Phase 1

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

Completed
NCT05517525Phase 1

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Completed
NCT05673603Phase 1

A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

Completed
NCT05355935Phase 1

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11